

# Tal Patalon

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9590564/publications.pdf>

Version: 2024-02-01

21  
papers

2,463  
citations

567281

15  
h-index

794594

19  
g-index

45  
all docs

45  
docs citations

45  
times ranked

3635  
citing authors

#	ARTICLE	IF	CITATIONS
1	Initial report of decreased SARS-CoV-2 viral load after inoculation with the BNT162b2 vaccine. <i>Nature Medicine</i> , 2021, 27, 790-792.	30.7	421
2	Correlation of SARS-CoV-2-breakthrough infections to time-from-vaccine. <i>Nature Communications</i> , 2021, 12, 6379.	12.8	214
3	Viral loads of Delta-variant SARS-CoV-2 breakthrough infections after vaccination and booster with BNT162b2. <i>Nature Medicine</i> , 2021, 27, 2108-2110.	30.7	204
4	The Effectiveness of the Two-Dose BNT162b2 Vaccine: Analysis of Real-World Data. <i>Clinical Infectious Diseases</i> , 2022, 74, 472-478.	5.8	152
5	Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Naturally Acquired Immunity versus Vaccine-induced Immunity, Reinfections versus Breakthrough Infections: A Retrospective Cohort Study. <i>Clinical Infectious Diseases</i> , 2022, 75, e545-e551.	5.8	130
6	Odds of Testing Positive for SARS-CoV-2 Following Receipt of 3 vs 2 Doses of the BNT162b2 mRNA Vaccine. <i>JAMA Internal Medicine</i> , 2022, 182, 179.	5.1	128
7	Vaccination with BNT162b2 reduces transmission of SARS-CoV-2 to household contacts in Israel. <i>Science</i> , 2022, 375, 1151-1154.	12.6	109
8	Waning effectiveness of the third dose of the BNT162b2 mRNA COVID-19 vaccine. <i>Nature Communications</i> , 2022, 13, .	12.8	104
9	Assessment of Effectiveness of 1 Dose of BNT162b2 Vaccine for SARS-CoV-2 Infection 13 to 24 Days After Immunization. <i>JAMA Network Open</i> , 2021, 4, e2115985.	5.9	96
10	Community-level evidence for SARS-CoV-2 vaccine protection of unvaccinated individuals. <i>Nature Medicine</i> , 2021, 27, 1367-1369.	30.7	78
11	Multi-Institutional Validation of a Mammography-Based Breast Cancer Risk Model. <i>Journal of Clinical Oncology</i> , 2022, 40, 1732-1740.	1.6	71
12	Short term, relative effectiveness of four doses versus three doses of BNT162b2 vaccine in people aged 60 years and older in Israel: retrospective, test negative, case-control study. <i>BMJ</i> , The, 0, , e071113.	6.0	62
13	Waning of SARS-CoV-2 booster viral-load reduction effectiveness. <i>Nature Communications</i> , 2022, 13, 1237.	12.8	52
14	The Incidence of SARS-CoV-2 Reinfection in Persons With Naturally Acquired Immunity With and Without Subsequent Receipt of a Single Dose of BNT162b2 Vaccine. <i>Annals of Internal Medicine</i> , 2022, 175, 674-681.	3.9	45
15	Kinetics of SARS-CoV-2 anti-S IgG after BNT162b2 vaccination. <i>Vaccine</i> , 2021, 39, 5337-5340.	3.8	31
16	BNT162b2 mRNA Vaccine Effectiveness Given Confirmed Exposure: Analysis of Household Members of Coronavirus Disease 2019 Patients. <i>Clinical Infectious Diseases</i> , 2022, 75, e734-e740.	5.8	20
17	SARS-CoV-2 RT-qPCR Test Detection Rates Are Associated with Patient Age, Sex, and Time since Diagnosis. <i>Journal of Molecular Diagnostics</i> , 2022, 24, 112-119.	2.8	12
18	Evaluating red blood cell distribution width from community blood tests as a predictor of hospitalization and mortality in adults with SARS-CoV-2: a cohort study. <i>Annals of Medicine</i> , 2021, 53, 1410-1418.	3.8	9

#	ARTICLE	IF	CITATIONS
19	Dynamics in COVID-19 symptoms during different waves of the pandemic among children infected with SARS-CoV-2 in the ambulatory setting. <i>European Journal of Pediatrics</i> , 2022, 181, 3309-3318.	2.7	7
20	A multi-layer model for the early detection of COVID-19. <i>Journal of the Royal Society Interface</i> , 2021, 18, 20210284.	3.4	2
21	Early Oxygen Treatment Measurements Can Predict COVID-19 Mortality: A Preliminary Study. <i>Healthcare (Switzerland)</i> , 2022, 10, 1146.	2.0	0